COVAXX, a subsidiary of United Biomedical, has received US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) approval for UBI SARS-CoV-2 ELISA, its Covid-19 antibody test. The test will evaluate individuals’ adaptive immune response to the SARS-CoV-2 virus, indicating either a recent or prior infection, as well as the presence of antibody levels after being vaccinated.

LumiraDx, a point-of-care diagnostic testing company, has sought approvals for the use of its SARS-CoV-2 antigen test in Japan and Brazil. The test will now be available to infected individuals in more than 30 nations globally. In addition to these authorisations, Italy has also recommended the expansion of its next-generation microfluidic technology for Covid-19 testing.

Anteotech, a medical diagnostic tools developer, has been awarded a $1.4m contract to advance the development and commercialisation of its Covid-19 antigen rapid test (RAT). The Queensland Government Grant will fund the finalisation and marketing of its proposed 15-minute point-of-care Covid-19 RAT, which harnesses Anteotech’s nanoparticle surface management technology, AnteoBind™, and a Europium particle in the detection of the SARS-CoV-2 antigen.

eMed, a digital point-of-care solutions company, has announced a partnership with the State of Ohio to supply, as well as administer approximately two million virtually guided, BinaxNOW™ at-home Covid-19 rapid tests, which can deliver results within minutes. The eMed rapid tests will enhance the reach and accessibility of home testing across organisations, states, and individuals.